Images List Premium Download Classic

Codon

Codon-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Solid oral pharmaceutical composition
Lupin Inc.
December 07, 2017 - N°20170348239

A solid oral pharmaceutical composition of promethazine, hydrocodone and acetaminophen, or a pharmaceutically acceptable salt thereof is provided. The composition comprises promethazine formulated for immediate release, both hydrocodone and acetaminophen formulated for controlled release, and at least one of the hydrocodone and acetaminophen formulated for immediate release.
Sequence variants
Sandoz Ag
November 30, 2017 - N°20170342422

Amino acid residue misincorporations are necessarily found in sequence variants at low concentrations in admixture with expressed polypeptides, resulting from one or more base mismatches within codons susceptible to amino acid residue misincorporation during transcription and/or translation. The invention provides a method of optimizing the coding sequences of a polynucleotide that encodes a polypeptide, wherein at least one codon ...
Cell surface display of polypeptide isoforms by stop codon readthrough
Sandoz Ag
November 30, 2017 - N°20170342403

Also provided are host cells, comprising respectively designed heterologous nucleic acids and methods for producing a polypeptide using respective host cells.
Codon Patent Pack
Download 98+ patent application PDFs
Codon Patent Applications
Download 98+ Codon-related PDFs
For professional research & prior art discovery
inventor
  • 98+ full patent PDF documents of Codon-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for improving intestinal health using extracts of codonopsis lanceolata
Korea Institute Of Science And Technology
November 30, 2017 - N°20170340690

Disclosed is a method for improving intestinal microflora, which includes administering an extract of codonopsis lanceolata of an amount effective for improving intestinal microflora to a subject in need thereof. The extract can promote the proliferation of beneficial intestinal bacteria and suppress the proliferation of harmful bacteria. Also, the extract can improve intestinal health or intestinal function and improve defecation ...
Oxycodone formulations
Purdue Pharma L.p.
November 30, 2017 - N°20170340626

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0. 6 to 1. 0 or 0. 7 to 1 after oral administration at steady state to patients and methods thereof
Process for the formation of hydrocodone bitatrate
Cambrex Charles City, Inc.
November 16, 2017 - N°20170327511

There is provided a novel process for the preparation of a hydrocodone salt. In particular, there is provided a novel process for the preparation of a free-flowing slurry of a hydrocodone salt, for example, a free-flowing slurry of hydrocodone bitartrate hemipentahydrate.
Codon Patent Pack
Download 98+ patent application PDFs
Codon Patent Applications
Download 98+ Codon-related PDFs
For professional research & prior art discovery
inventor
  • 98+ full patent PDF documents of Codon-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical dosage forms
"nextgen" Company Limited
November 02, 2017 - N°20170312226

This invention relates to pharmaceutical dosage forms for delivery of drugs susceptible to abuse, such as, for example, oxycodone and/or oxymorphone.
Cell lines
Medimmune Limited
October 26, 2017 - N°20170306381

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses pylrs and trnapyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of trnapyl expression on ...
Codon optimized polynucleotide for high level expression of crm197
Biological E Limited
October 26, 2017 - N°20170306302

The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide crm197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression ...
Genetically expanded cell free protein synthesis systems, methods and kits
B.g Negev Technologies And Applications Ltd., At Ben-gurion University
October 12, 2017 - N°20170292139

This invention relates to methods of producing a rare amino acid- or non-natural amino acid-containing protein in a cell free protein synthesis system and kits for use in and for accomplishing same. Specifically, the methods comprise the steps of expressing at least one orthogonal suppressor trna (o-trna)/aminoacyl-trna synthetase (aars) pair or derivatives thereof specific for incorporation of a rare ...
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
The Trustees Of The University Of Pennsylvania
October 12, 2017 - N°20170292132

Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (orf) for a protein under the control of regulatory sequences which direct expression of the product in cell, which orf has been modified to preferentially increase expression levels in a selected ...
Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
The Regents Of The University Of California
October 05, 2017 - N°20170283481

Disclosed are invariant natural killer t (inkt) cells engineered using hematopoietic stem and progenitor cells (hspcs) and methods of making and using thereof. Specifically, the engineered cells inkt are genetically modified to contain at least one exogenous invariant natural killer t cell receptor (inkt tcr) nucleic acid molecule. Further disclosed are inkt tcr nucleotide sequences and codon optimized sequences for ...
Proteolytic inactivation of select proteins in bacterial extracts for improved expression
Sutro Biopharma, Inc.
October 05, 2017 - N°20170283469

The present disclosure provides modified proteins that are capable of being cleaved by the protease ompt1. The proteins can be modified in an exposed surface motif to incorporate ompt1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified rf1. The disclosure further provides methods ...
Codon Patent Pack
Download 98+ patent application PDFs
Codon Patent Applications
Download 98+ Codon-related PDFs
For professional research & prior art discovery
inventor
  • 98+ full patent PDF documents of Codon-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods to treat aids
University Of Massachusetts
September 14, 2017 - N°20170258892

Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins. The synthetic, codon-optimized dnas encoding one or more hiv proteins are a combination of different nucleic acids, such as dna plasmids, ...
Multivalent brucella vaccine for protection against mycobacterial infections and methods of using the same
Virginia Tech Intellectual Properties, Inc.
August 31, 2017 - N°20170246282

Provided herein is a multivalent brucella vaccine expressing at least one heterologous m. Tuberculosis antigen. The vaccines described herein serve as an environmentally safe bivalent vaccine for protection against brucella and mycobacterium infections simultaneously. In particular, a multivalent vaccine comprising a brucella strain transformed with a vector that expresses at least one m. Tuberculosis antigen, where the m. Tuberculosis antigen(...
Pharmaceutical composition for treating infertility, and preparation method and use thereof
Sichuan Sainthood Biotech Co., Ltd.
August 31, 2017 - N°20170246230

The present invention provides a drug combination for the treatment of infertility and its crude drug comprises the medical ingredients with their weight proportions listed as below: 10-20 amounts by weight of rehmannia, 10-20 amounts by weight of chinese peony, 10-20 amounts by weight of asiatic dogwood, 10-20 amounts by weight of chinese yam, 10-20 amounts by weight of poria, 15...
Adeno-associated virus vectors for treatment of glycogen storage disease
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services
August 17, 2017 - N°20170233763

The present disclosure describes improved adeno-associated virus (aav) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type ia (gsd-ia). Described are recombinant nucleic acid molecules, vectors and recombinant aav that include a g6pc promoter/enhancer, a synthetic intron, a g6pc coding sequence (such as a wild-type or codon-optimized g6pc ...
Site-specific incorporation of phosphoserine into proteins in escherichia coli
Yale University
August 17, 2017 - N°20170233749

Nucleic acids encoding mutant elongation factor proteins (ef-sep), phosphoseryl-trna synthetase (seprs), and phosphoseryl-trna (trnasep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, seprs preferentially aminoacrylates trnasep with o-phosphoserine and the trnasep recognizes at least one codon such as a stop codon. Due to the negative charge of the phosphoserine, sep-trnasep ...
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
Baxalta Gmbh
August 17, 2017 - N°20170233455

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.
Method for gene optimization
Genective, S.a.
August 10, 2017 - N°20170226524

The invention relates to method of modifying a coding sequence encoding a non-plant protein, comprising the steps of optimizing said coding sequence by codon substitution, thereby obtaining an optimized coding sequence which encodes said non-plant protein; and re-introducing at least one wild-type polyadenylation motif sequence at its position within said optimized gene sequence.
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
Baxalta Gmbh
August 10, 2017 - N°20170226188

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.
Loading